TY - JOUR T1 - Assessment of effective mitigation and prediction of the spread of SARS-CoV-2 in Germany using demographic information and spatial resolution JF - medRxiv DO - 10.1101/2020.12.18.20248509 SP - 2020.12.18.20248509 AU - Martin J. Kühn AU - Daniel Abele AU - Tanmay Mitra AU - Wadim Koslow AU - Majid Abedi AU - Kathrin Rack AU - Martin Siggel AU - Sahamoddin Khailaie AU - Margrit Klitz AU - Sebastian Binder AU - Luca Spataro AU - Jonas Gilg AU - Jan Kleinert AU - Matthias Häberle AU - Lena Plötzke AU - Christoph D. Spinner AU - Melanie Stecher AU - Xiao Xiang Zhu AU - Achim Basermann AU - Michael Meyer-Hermann Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/12/22/2020.12.18.20248509.abstract N2 - Non-pharmaceutical interventions (NPIs) are important to mitigate the spread of infectious diseases as long as no vaccination or outstanding medical treatments are available. We assess the effectiveness of the sets of non-pharmaceutical interventions that were in place during the course of the Coron-avirus disease 2019 (Covid-19) pandemic in Germany. Our results are based on hybrid models, combining SIR-type models on local scales with spatial resolution. In order to account for the age-dependence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we include realistic pre-pandemic and recently recorded contact patterns between age groups. The implementation of non-pharmaceutical interventions will occur on changed contact patterns, improved isolation, or reduced infectiousness when, e.g., wearing masks. In order to account for spatial heterogeneity, we use a graph approach and we include high-quality information on commuting activities combined with traveling information from social networks. The remaining uncertainty will be accounted for by a large number of randomized simulation runs. Based on the derived factors for the effectiveness of different non-pharmaceutical interventions over the past months, we provide different forecast scenarios for the upcoming time.Mathematics Subject Classification (2010) 00A72 · 65L05 · 68U20Competing Interest StatementDr. Spinner reports no conflict of interest during the conduct of the study; but personal fees from AbbVie, grants and personal fees from Aperion, grants and personal fees from Janssen-Cilag, grants and personal fees from Gilead Sciences, personal fees from molecular partners, grants and personal fees from MSD, grants and personal fees from ViiV Healthcare/GSK, outside the submitted work. All other authors declare that they have no conflict of interest.Funding StatementThe work of M. Haeberle and X. Zhu is supported by the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No. [ERC-2016-StG-714087], Acronym: So2Sat). This work has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101003480 and by the Initiative and Networking Fund of the Helmholtz Association. It was supported by German Federal Ministry of Education and Research for the project CoViDec (FKZ: 01KI20102). The funding bodies had no role in the design of the study, collection, analysis, and interpretation of the results, or writing the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Does not apply.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used was mainly obtained from publicly available resources and references are provided. Data used in the software will be made publicly available with the software framework. ER -